We are the only biotechnology therapeutics discovery and development company able to define causal biology from disease-associated variants on a genome-wide scale, enabling the rapid identification of new, high-confidence, first-in-class therapeutic targets for common diseases, with blockbuster potential.

Unlocking decades worth of genetic data and providing unparalleled validation via our proprietary 3D multi-omics platform and data-rich human cell type-specific atlas, we are able to expedite drug discovery and precision medicine.

Our 3D multi-omics platform is the only genome-wide, hypothesis-free technology able to translate massive amounts of disease-associated variant data into causal biology on a cell-type-specific basis. This approach supports both target prioritization, more than doubling the probability of success, and target identification, vastly increasing the number of novel disease targets that can be identified, more efficiently and in a fraction of the time previously possible. It also allows the stratification of patients into responder groups to improve and accelerate clinical trials.